Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

Background The WHO Global Health Sector Strategy aims to reduce worldwide syphilis
incidence by 90% between 2018 and 2030. If this goal is to be achieved, interventions that target …

… A phase I clinical study using NPe6 suggested that the optimal conditions in terms of safety
and efficacy were intravenous administration of 40 mg/m 2 and laser irradiation at 4 hours …

Background Among patients with resectable early-stage non–small-cell lung cancer (NSCLC),
a perioperative approach that includes both neoadjuvant and adjuvant immune …

Background Lobectomy is the standard of care for early-stage non-small-cell lung cancer (NSCLC).
The survival and clinical benefits of segmentectomy have not been investigated in a …

… Tsuboi can be contacted at mtsuboi@ east . ncc . go . … Tsuboi and Herbst contributed equally
to this article. … Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced nonsmall-…

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …

The balance of programmed death-1 (PD-1)-expressing CD8 + T cells and regulatory T (Treg)
cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …

Background In a previous phase 3 trial of adjuvant chemotherapy after resection of non–small-cell
lung cancer, a combination of uracil and tegafur (often referred to as UFT) taken orally …

Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the success
of this approach is very variable; therefore, biomarkers predictive of clinical efficacy are …